title: [Experience in coenzyme Q10 application in complex therapy of coronary heart disease with dyslipidemia].
abstract: The subjects of the study were 43 patients with II- III functional class coronary heart disease (CHD) and dyslipidemia, who received conventional cardial therapy. The patients were divided into two groups: group I (26 subjects) received vasilip, a simvastatin generic, in a dose of 20 mg a day; group 11 (17 subjects) received vasilip in a dose of 20 mg a day plus cudesan in a dose of 1 ml a day, which contained 30 mg of ubiquinone Q 10 and 4.5 mg of alpha-tocopherol. Effects of the therapies on blood lipids, their peroxides, and the antioxidative status of blood were studied. After one month, vasilip was effective in achieving the target level of low-density lipoprotein cholesterol in 62% of group I patients and 65% of group II patients; at the same time, its use led to a significant increase in the level of primary and secondary lipid peroxidation (LP) products (25% and 29%, respectively), and lowering of the antioxidative status of blood, which consisted in a decrease in ceruloplasmin (CP) serum level and CP: transferrin (CP:TF) ratio by 6% in group I patients. The use of cudesan in combination with vasilip led to a significant decrease in the level of primary and secondary LP products (30% and 29%, respectively), and an increase in the level of serum CP by 25.7%, and CP: TF ratio by 12.5%.
authors.forename: O L
authors.initials: OL
authors.lastname: Belaia
authors.forename: V I
authors.initials: VI
authors.lastname: Kalmykova
authors.forename: L A
authors.initials: LA
authors.lastname: Ivanova
authors.forename: L G
authors.initials: LG
authors.lastname: Kochergina
mesh_terms: D002570:Ceruloplasmin / Q000627:therapeutic use; D003067:Coenzymes; D003327:Coronary Disease / Q000188:drug therapy* / Q000453:epidemiology*; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000188:drug therapy* / Q000453:epidemiology*; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D019821:Simvastatin / Q000494:pharmacology / Q000627:therapeutic use; D014168:Transferrin / Q000378:metabolism; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D003067:Coenzymes; D000960:Hypolipidemic Agents; D014168:Transferrin; D014451:Ubiquinone; D019821:Simvastatin; D002570:Ceruloplasmin; C024989:coenzyme Q10